United States Uterine Fibroids Treatment Devices Market By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment), By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Others), By Region and Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 614.72 Million
CAGR (2026-2031)	8.93%
Fastest Growing Segment	Minimally Invasive Treatment
Largest Market	North-East
Market Size (2031)	USD 1026.98 Million

Market Overview

The United States Uterine Fibroids Treatment Devices Market will grow from USD 614.72 Million in 2025 to USD 1026.98 Million by 2031 at a 8.93% CAGR. The United States Uterine Fibroids Treatment Devices Market encompasses medical instruments and systems designed for the management and removal of benign uterine growths. These devices include tools for radiofrequency ablation, focused ultrasound systems, embolization catheters, and various surgical instruments used in laparoscopic or hysteroscopic myomectomy procedures. Primary drivers supporting this market's expansion include the increasing prevalence of uterine fibroids among women and advancements in minimally invasive treatment technologies.

The rising incidence of symptomatic cases necessitates effective interventions. According to a June 2025 consumer update from the United States Food and Drug Administration (FDA), up to 80% of women develop uterine fibroids by age 50. The growing demand for uterus-preserving alternatives to hysterectomy also fuels market growth. However, a significant challenge impeding market expansion is the high cost of advanced treatment devices and limited access to specialized care, particularly in underserved regions.

Key Market Drivers

Rising Fibroid Prevalence Drives Demand for Diagnostic and Treatment Devices
The increasing prevalence of uterine fibroids significantly drives demand within the United States Uterine Fibroids Treatment Devices Market. These benign growths affect a substantial portion of the female population, often leading to debilitating symptoms requiring medical intervention. According to the Society for Women's Health Research, in September 2025, an estimated 26 million women aged 15 to 50 in the United States are affected by uterine fibroids. This high incidence creates a consistent patient pool in need of diagnostic tools and therapeutic devices. Furthermore, a growing emphasis on women's health awareness campaigns ensures that more women are diagnosed and seek appropriate treatment, directly impacting the adoption of various uterine fibroid treatment devices.

Minimally Invasive Therapies Drive Growth in Uterine Fibroid Device Market
Advancements in minimally invasive and non-invasive procedures also substantially fuel market expansion. These technological innovations offer patients less painful options with shorter recovery times compared to traditional open surgeries. For instance, according to Hologic, Inc.'s fiscal fourth quarter results, surgical revenue, significantly influenced by uterine fibroid treatment devices like MyoSure and Fluent, grew 10.2% in November 2025, demonstrating the uptake of such advanced tools. The continuous development and refinement of radiofrequency ablation, focused ultrasound, and advanced hysteroscopic systems enhance treatment efficacy and patient satisfaction, thereby accelerating market growth. The broader U.S. medtech industry, which encompasses these innovations, generated over $250 billion in annual output in July 2025, underscoring the dynamic environment for medical device development and adoption.

Download Free Sample Report

Key Market Challenges

Cost and Access Barriers to Advanced Uterine Fibroids Devices
The high cost of advanced treatment devices and limited access to specialized care significantly impede the expansion of the United States Uterine Fibroids Treatment Devices Market. The substantial capital expenditure required for acquiring and maintaining advanced medical instruments can deter healthcare providers, particularly smaller clinics and hospitals, from investing in these technologies. This financial barrier directly restricts the availability of innovative, less-invasive treatment options for uterine fibroids, thereby limiting market penetration and patient access.

Specialist Shortages Impede Device Utilization for Uterine Fibroids Care
Furthermore, the scarcity of specialized gynecological care, especially in underserved regions, compounds this challenge. Even when advanced devices are available, a lack of qualified medical professionals to operate them creates a bottleneck in treatment delivery. According to a January 2026 statement by the American College of Obstetricians and Gynecologists (ACOG), the national supply of OB-GYNs met only 93.4% of the demand in 2025, with pronounced geographic disparities leading to severe shortfalls in nonmetropolitan areas. This insufficient specialist workforce directly hampers the effective utilization and growth of the uterine fibroids treatment devices market by constraining the number of procedures performed.

Key Market Trends

Fertility-Sparing Device Innovations in the U.S. Fibroid Market
The increasing focus on fertility-sparing device innovations is a significant trend in the United States Uterine Fibroids Treatment Devices Market, driven by a growing desire among patients to preserve reproductive potential. This trend stimulates the development and adoption of technologies that effectively treat fibroids while minimizing uterine impact. According to the American College of Obstetricians and Gynecologists in their "2024 Clinical Guidance on Fibroid Management", U.S. hysterectomy volumes for fibroids declined from approximately 200,000 in 2020 to an estimated 165,000 in 2025, demonstrating a clear shift towards uterus-preserving alternatives such as uterine artery embolization and MR-guided focused ultrasound. This preference fuels research and product innovation in less invasive myomectomy techniques and advanced ablation systems for fertility preservation, expanding the market for specialized devices.

AI-Enhanced Imaging for Improved Fibroid Treatment Precision
Another impactful trend is the integration of artificial intelligence (AI) in imaging for enhanced treatment precision. AI technologies are increasingly applied to improve diagnostic accuracy, refine treatment planning, and guide procedures with greater exactitude, optimizing outcomes for uterine fibroid interventions. These advancements support more precise application of existing treatment devices and facilitate the uptake of novel therapies requiring accurate targeting. According to Contemporary OB/GYN, January 2026, in 'Top FDA approvals in women's health in 2025', the FDA cleared the Sonio Suspect AI model for detecting fetal anomalies on February 24, 2025, offering a 22-point improvement in reader performance. This regulatory approval highlights the growing acceptance and utility of AI in advancing diagnostic and procedural precision within gynecological imaging, directly benefiting uterine fibroid treatment planning and execution.

Segmental Insights

Growth Drivers for Minimally Invasive Fibroid Treatments
In the United States Uterine Fibroids Treatment Devices Market, the Minimally Invasive Treatment segment is experiencing rapid growth. This surge is primarily driven by significant patient preference for procedures offering shorter recovery times, reduced pain, and lower complication risks compared to traditional surgical methods. Furthermore, these advanced techniques frequently allow for uterus preservation, which is a crucial consideration for many women. Ongoing innovations, such as MRI-guided focused ultrasound and radiofrequency ablation devices, along with clearances from regulatory bodies like the U.S. Food and Drug Administration (FDA), are enhancing treatment precision and patient outcomes, thereby accelerating market adoption.

Regional Insights

North-East Emerges as Leader in the U.S. Uterine Fibroids Treatment Devices Market Driven by Infrastructure, Spending, and Research
The North-East region emerges as the leading segment within the United States Uterine Fibroids Treatment Devices Market, primarily driven by its established and sophisticated healthcare infrastructure. This dominance is further propelled by substantial healthcare expenditure and a strong concentration of leading medical research institutions, fostering advanced research and development activities in gynecological care. The region demonstrates a high adoption rate of innovative, minimally invasive, and non-invasive treatment devices, reflecting a technologically progressive approach to patient care. Moreover, the presence of favorable reimbursement policies, coupled with increased patient awareness regarding available advanced treatment options, significantly contributes to market growth and the region's prominent position.

Recent Developments

• In October 2025, Medtronic plc initiated the U.S. Investigational Device Exemption (IDE) clinical study, "Embrace Gynecology," to assess the safety and effectiveness of its Hugo™ robotic-assisted surgery (RAS) system for gynecological procedures. This study included the treatment of benign conditions such as uterine fibroids, alongside gynecological cancers, thereby expanding Medtronic's efforts to provide minimally invasive surgical options. The initiation of this clinical trial represented a significant breakthrough in research for the United States Uterine Fibroids Treatment Devices Market, aiming to evaluate new robotic-assisted surgical technologies for less invasive interventions.
• In October 2025, Meditrina Inc. continued to advance its Aveta System, which is designed for minimally invasive treatment options in women's health, including the removal of intrauterine fibroids. The Aveta System is a mechanical hysteroscopy system intended for the removal and retrieval of intrauterine tissue. This device allows healthcare providers to visualize and treat intrauterine conditions with precision, minimizing patient discomfort and often avoiding traditional surgical incisions. The ongoing presence and development of the Aveta System contribute to the evolving landscape of uterine fibroids treatment devices in the United States, emphasizing less invasive patient care.
• In October 2024, Hologic, Inc., a prominent women's health medical technology company, finalized an agreement to acquire Gynesonics, Inc. for approximately $350 million. Gynesonics, a privately held medical device company, is recognized for its Sonata System, which offers diagnostic intrauterine imaging and transcervical treatment for symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. This acquisition was intended to bolster Hologic's gynecologic surgical business by expanding its portfolio with Gynesonics' minimally invasive solution, offering surgeons a broader array of treatment options for women afflicted by fibroids. This strategic collaboration significantly impacted the United States Uterine Fibroids Treatment Devices Market by consolidating key technologies.
• In September 2024, Gynesonics, Inc., prior to its acquisition by Hologic, introduced a significant advancement with its new SMART OS™ 2.4 software release for the Sonata System. This software update was designed to enhance the transcervical fibroid ablation procedure by enabling physicians to treat uterine fibroids more quickly. The Sonata System is an incision-free, uterus-preserving device that uses real-time intrauterine ultrasound guidance and radiofrequency energy to ablate fibroids. This new software represented a product enhancement aimed at improving the efficiency and precision of minimally invasive uterine fibroid treatments within the United States market.

Key Market Players

• Boston Scientific Corporation
• Medtronic plc
• Hologic Inc.
• CooperSurgical Inc.
• Olympus Corporation
• Karl Storz SE & Co. KG
• Johnson & Johnson
• GE HealthCare Technologies Inc.
• Siemens Healthineers AG
• Fujifilm Holdings Corporation

By Mode of Treatment	By Technology	By Region
Invasive Treatment Minimally Invasive Treatment Non-invasive Treatment	Surgical Techniques Laparoscopic Techniques Ablation Techniques Others	Northeast Midwest South West

Report Scope:

In this report, the United States Uterine Fibroids Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Uterine Fibroids Treatment Devices Market, By Mode of Treatment:

• Invasive Treatment
• Minimally Invasive Treatment
• Non-invasive Treatment

• United States Uterine Fibroids Treatment Devices Market, By Technology:

• Surgical Techniques
• Laparoscopic Techniques
• Ablation Techniques
• Others

• United States Uterine Fibroids Treatment Devices Market, By Region:

• Northeast
• Midwest
• South
• West